Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
The emergence of oral selective estrogen receptor degraders (SERDs) offers the opportunity to address unmet needs for patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer. This program focuses on incorporating oral SERDs into the standard of care, as showcased in challenging patient cases that highlight key clinical trial data to illustrate and justify treatment decisions.
This educational activity is an archive of the live virtual symposium held on August 2, 2025.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement best practices for biomarker testing to manage patients with HR+/HER2– breast cancer
- Assess recent practice-changing evidence for the use of oral SERDs in patients with HR+/HER2– breast cancer
- Create individualized care plans to optimize the use of oral SERDs in patients with HR+/HER2– metastatic breast cancer
Ana C. Garrido-Castro, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Triple-Negative Breast Cancer Research
Susan F. Smith Center for Women’s Cancers
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bicycle Therapeutics, Daiichi Sankyo, Gilead Sciences, Novartis, Pfizer, Roche/Genentech, TD Cowen; Grant/Research Funding (to institution): 4D Path, AstraZeneca, Bicycle Therapeutics, Biovica, Bristol Myers Squibb, Daiichi Sankyo, Foundation Medicine, Gilead Sciences, Merck, Novartis, Precede Biosciences, Zenith Epigenetics; Travel/Accommodations: AstraZeneca, Daiichi Sankyo, Gilead Sciences, Merck, Novartis, Pfizer, Roche/Genentech.
Pedram Razavi, MD, PhD
Assistant Attending, Department of Medicine
Director, Breast Translational Program and Breast Molecular Tumor Board
Director, Liquid Biopsy and Cancer Genomics
MSK Global Biomarker Development Program
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Epic Sciences, Foundation Medicine, Guardant, Inivata, Lilly/Loxo, Myriad Genetics, Natera, Novartis, Paige.ai, Pfizer, Prelude Therapeutics, SAGA Diagnostics, Tempus; Grant/Research Funding (to institution): AstraZeneca, Biotheranostics, Biovica, Breast Cancer Alliance, Epic Sciences, Foresight, Grail, Guardant, Illumina, Inivata, Invitae/ArcherDX, Komen, Myriad Genetics, NIH, Novartis, Personalis, Tempus.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here